SCD Clinical Trial
Official title:
Exploring Near Infrared Spectroscopy (NIRS) Technologies for Assessment of Muscle Physiology, Tissue Oxygenation, and Blood Flow in Patients With Sickle Cell Disease (SCD)
Sickle cell disease (SCD) is an inherited disorder of the blood. SCD can injure the smallest blood vessels, which can cause pain and damage organs all over the body. Some treatments are available, but researchers need better ways to monitor the effects of these treatments. An imaging technique called near infrared spectroscopy (NIRS) may be helpful. Objective: To test NIRS as a tool for measuring oxygen levels, blood flow, and the makeup of skin and muscle in patients with SCD. Eligibility: People aged 18 years and older with SCD. Healthy volunteers are also needed as a comparison for the changes in SCD patients. Design: Participants will be screened. They will have a physical exam, and 1 teaspoon of blood will be drawn. Participants will have NIRS testing on their second visit. Probes will be placed on their skin. A blood pressure cuff will be placed on their arm. The cuff will be filled with air for up to 5 minutes and then released. Participants may be asked to breathe at a certain rate or hold their breath during these measurements. At this visit, participants will also have an ultrasound exam to get images of their heart. They will be monitored while they walk for 6 minutes. They will have 1 tablespoon of blood drawn. Their height, weight, and vital signs will be measured. Participants may be asked to return for up to 4 additional visits for NIRS testing within 120 days, but this is optional. The visits must be at least 3 days apart. Each visit will last up to an hour....
Status | Recruiting |
Enrollment | 50 |
Est. completion date | February 28, 2025 |
Est. primary completion date | February 28, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | - INCLUSION CRITERIA: Sickle Cell Disease - Individuals with confirmed sickle cell disease (HbSS and S beta 0 genotypes) - 18 years of age and older - Willingness and capacity to provide informed consent - Individuals must be on stable does of Hydroxyurea for 90 days prior to baseline visit Ethnically matched controls - Individuals with HbAA genotype - 18 years of age and older - Willingness and capacity to provide informed consent EXCLUSION CRITERIA: Sickle Cell Disease - Pain crisis requiring parenteral treatment within 4 weeks of screening/enrollment - Blood transfusion within 60 days or exchange transfusion within 90 days of screening/enrollment - Use of Oxbryta (voxelotor), Adakveo (crizanlizumab), and/or Endari (L-glutamine) within the 12 weeks prior to signing consent - Women who are currently pregnant - Presence of an arterial-venous shunt, recent axillary node dissection, or any deformity or surgical history that interferes with proper access for brachial cuff occlusion procedure of the extremities - Mobility difficulties causing the inability to complete 6-minute walk test Ethnically matched controls - Women who are currently pregnant - Presence of an arterial-venous shunt, recent axillary node dissection, or any deformity or surgical history that interferes with proper access for brachial cuff occlusion procedure of the extremities - Mobility difficulties causing the inability to complete 6-minute walk test - Blood transfusion within 60 days or exchange transfusion within 90 days of screening/enrollment |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To quantify baseline hemodynamic function in SCD subjects at steady state utilizing NIRS in parallel with clinical assessments of cardiovascular function, including the 6-minute walk test (6MWT), pro BNP levels and transthoracic echocardiogram. | Baseline NIRS measurements will permit real time assessment of peripheral tissue hemodynamics, including oxygenation and blood flow, in relation to established markers of cardiovascular health in subjects with SCD, including the 6MWT, TTE, and pro BNP levels | 120 days | |
Secondary | To assess baseline tissue hemodynamic function utilizing NIRS in ethnically-matched healthy control subjects without (AA) and with sickle cell trait (AS) as compared to baseline NIRS assessments in patients with SCD. | This will permit comparison of peripheral tissue hemodynamics, including blood flow and oxygenation, and cardiovascular clinical outcomes (6MWT, TTE, pro BNP) in subjects with SCD and ethnically-matched healthy volunteer subjects. NIRS results may validate abnormal tissue hemodynamic responses observed in subjects with SCD as compared to controls | 120 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04779671 -
Effects of the Fully Immersive VR Cognitive Training Based on Leisure Activities for the Elderly With MCI and SCD.
|
N/A | |
Completed |
NCT02065596 -
Hematopoietic Stem Cell Transplant for Sickle Cell Disease
|
Phase 1 | |
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Recruiting |
NCT03926351 -
High Dose Omega 3 in People at Risk for Dementia
|
Phase 2 | |
Recruiting |
NCT06335836 -
The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)
|
||
Not yet recruiting |
NCT05682469 -
Effects and Mechanism of the Fully Immersive Virtual Reality Cognitive Training Based on Leisure Activities
|
N/A | |
Recruiting |
NCT06120361 -
The Swedish BioFINDER - Primary Care Study
|
||
Recruiting |
NCT06122415 -
The Swedish BioFINDER - Memory Clinic Study
|
||
Completed |
NCT01384435 -
A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
|
Phase 2 |